Document:

EX-10.14

 Exhibit 10.14 

Commercial Sublease 
  

	1.	Parties 

 This sublease is made by Sublandlord, eGain Corporation, with a principal place
of business at 1252 Borregas Avenue, and Subtenant, Adesto Technologies, with a principal place of business at 1250 Borregas Avenue, Sunnyvale, CA 94089. 
  

	2.	Property Subleased 

 Sublandlord is subleasing to Subtenant the premises at 1250 Borregas Avenue,
Sunnyvale, CA 94089. 
  

	3.	Original Lease and Subsequent Amendments 

 A. This subtenancy is subject to all
the terms and conditions of the Original Lease dated May 9, 2011 between D.R. Stephens, Landlord, and eGain Corporation, Tenant. 

B. Further, none of eGain’s rights under the First Amendment between D.R. Stephens, Landlord, and eGain Corporation, Tenant, are
forfeited. 
 C. The dates pertaining to eGain’s rent abatement and Tenant Improvements from Landlord are hereby amended to
accommodate the six month sublease and are accordingly pushed out six months. 
 D. Subtenant will do nothing and will not fail to
take any action that will create a breach by Sublandlord of any of the terms or conditions of the Original Lease. 
 E.
Notwithstanding anything contained in this sublease to the contrary, Subtenant is not assuming any obligations under the Original Lease and, for the avoidance of doubt, is not liable or responsible (legally, financially or otherwise) for any
acts or omissions of Sublandlord as Tenant under the Original Lease or their consequences. 
 F. Notwithstanding anything contained
in this sublease to the contrary, Sublandlord shall have no right to access or use the subleased premises except as provided in Paragraph 13. 
  

	4.	Term of Sublease 

 This sublease begins on August 5, 2015 and ends on February 4, 2016. 

 

	5.	Rent 

 Base Rent: $32,851.50 per month based on $1.50 per square foot, payable on the first day of each
month commencing August 1, 2015. Base Rent for the first month to be prorated for the 27 days of occupancy beginning August 5, 2015 in the amount of $28,612.60. 

	 	5.1.	Late Charges 

 Subtenant hereby acknowledges that late payment by Subtenant to Landlord of rent and other
sums due hereunder will cause Sublandlord to incur costs not contemplated by this Sublease, the exact amount of which will be extremely difficult to ascertain. Such costs include, but are not limited to, processing and accounting charges, and late
charges which may be imposed upon Sublandlord by the terms of its lease with Landlord. Accordingly, if any installment of rent or other sum due from Subtenant shall not be received by Sublandlord or Sublandord’s designee within five
(5) days after such amount shall be due, then, without any requirement for notice to Subtenant, Subtenant shall pay to Sublandlord a late charge equal to ten percent (10%) of such overdue amount. The parties hereby agree that such late
charge represents a fair and reasonable estimate of the costs Sublandlord will incur by reason of late payment by Subtenant. Notwithstanding of the foregoing, Sublandlord will not assess a late charge until Sublandlord has given written notice of
such late payment for the first late payment in any twelve (12) month period and after Subtenant has not cured such late payment within three (3) days from receipt of such notice. No other notices will be required during the following
twelve (12) months for a late charge to be incurred. Acceptance of such late charge be Sublandlord shall in no event constitute a waiver of Tenant’s Default or Breach with respect to such overdue amount, nor prevent Sublandlord from
exercising any of the other rights and remedies granted hereunder. In the event that a late charge is payable hereunder, whether or not collected, for three (3) consecutive installments of Base Rent, then notwithstanding Paragraph 4.1 or any
other provision of the Original Lease to the contrary, Base Rent shall, at Sublandlord’s option, become due and payable quarterly in advance. 
  

	 	5.2.	Common Area Operating Expenses 

 Subtenant’s share of Common Area Operating Expenses: Subtenant will
continue to pay the estimate based on the square footage formula used by Landlord to date but payment will be made to Sublandlord who will bill Subtenant. Landlord will bill Sublandlord for 100% of Common Area Operating Expenses beginning the
effective date of Subtenancy and continuing thereafter until the end of the extended Original Lease. The Landlord shall provide a true up of the actual Common Area Operating Expenses within 45 days of the end of Subtenant’s lease. 

 

	6.	Security Deposit 

 Subtenant will deposit $32,851.50 with Sublandlord as security for Subtenant’s
performance of this sublease with the execution of the sublease. Sublandlord will refund this security deposit to Subtenant at the end of the sublease if Subtenant returns the premises to Sublandlord in good condition (except for reasonable wear and
tear) and Subtenant has paid Sublandlord all sums due under this sublease. Otherwise, Sublandlord may deduct any amounts required to place the premises in good condition and to pay any sums due under the sublease. 

 

	7.	Notices From Landlord 

 If Landlord notifies Subtenant that Subtenant is in breach of any terms or
conditions in the Original Lease, Subtenant will immediately notify Sublandlord in writing. Subtenant will promptly cure any breach. Similarly, if Landlord notifies Sublandlord that Subtenant is in breach of the terms or conditions of the Original
Lease, Sublandlord will immediately notify Subtenant in writing. Subtenant will promptly cure any breach. 

	8.	Subletting and Assignment 

 Subtenant will not assign this sublease or further sublet any part of the
premises without the written consent of both Sublandlord and Landlord. Sublandlord will not unreasonably withhold such consent. 
  

	9.	Insurance 

 A. Subtenant and Sublandlord release each other from any liability to
the other for any property loss, property damage, or personal injury to the extent covered by insurance carried by the party suffering the loss, damage, or injury. 

B. Subtenant will carry public liability insurance; this insurance policy will include Sublandlord and Landlord as additional insured
parties. The public liability coverage for personal injury will be in at least the following amounts: 
 Five hundred dollars ($500.00) per
occurrence; 
 One hundred thousand dollars ($100,000.00) in any one year. 

C. Subtenant will give Sublandlord a certificate of insurance for all insurance policies that this sublease requires Subtenant to
obtain. 
  

	10.	Condition of Premises 

 Subtenant accepts the premises in “as is” condition. Sublandlord will
not make any modifications or improvements before the sublease term begins. 
  

	11.	Landlord’s Consent 

 This sublease will not be effective unless Landlord signs this sublease. 

 

	12.	Attorneys’ Fees 

 If either party brings a legal action arising out of a dispute over this
agreement, the losing party will reimburse the prevailing party for all reasonable costs and attorneys’ fees incurred by the prevailing party in the lawsuit. 
  

	13.	Additional Agreements 

 Sublandlord and Subtenant additionally agree that Sublandlord shall only have
access and use of the Subtenant’s conference room Trek from 8:00 am to 5:00 pm, Tuesdays and Thursdays. Except as provided in the immediately preceding sentence, Sublandlord shall have no right to access or use the subleased premises for any
purpose without Subtenant’s prior written consent which consent may be refused or conditional by Subtenant in its unfettered discretion. 
  

	14.	Entire Agreement 

 This is the entire agreement between the parties. It replaces and supersedes any and
all oral agreements between the parties, as well as any prior writings. 

	15.	Successors and Assignees 

 This agreement binds and benefits the heirs, successors, and assignees of the
parties. 
  

	16.	Notices 

 All notices about this sublease must be in writing and must be delivered either in person or in
a way that provides written documentation of delivery — for example, certified U.S. mail or a delivery service that provides evidence of delivery. 
  

	17.	Governing Law 

 This agreement will be governed by and construed in accordance with the laws of the state
of California. 
  

	18.	Counterparts 

 This sublease may be signed by the parties in different counterparts and the signature
pages combined will create a document binding on all parties. 
  

	19.	Modification 

 This sublease may be modified only by a written agreement signed by all the parties. 

 

	20.	Waiver 

 If one party waives any term or provision of this sublease at any time, that waiver will be
effective only for the specific instance and specific purpose for which the waiver was given. If either party fails to exercise or delays exercising any of its rights or remedies under this sublease, that party retains the right to enforce that term
or provision at a later time. 
  

	21.	Severability 

 If any court determines that any provision of this agreement is invalid or unenforceable,
any invalidity or unenforceability will affect only that provision and will not make any other provision of this agreement invalid or unenforceable. Provisions shall be modified, amended, or limited only to the extent necessary to render them valid
and enforceable. 

 eGain Corporation, a Delaware corporation 

 

							
	By: Charles Messman	 		 	Title: VP of Finance
				
	Signature:	 	   /s/ Charles Messman
	 		 	Date: 5/13/2015
			
	Adesto Technologies	 		 	
			
	By: Narbeh Derhacobian	 		 	Title: CEO
				
	Signature:	 	   /s/ Narbeh Derhacobian
	 		 	Date: 5/15/2015
			
	D.R. Stephens	 		 	
			
	By: Lane Stephen	 		 	Title: Manager
				
	Signature:	 	   /s/ Lane Stephen
	 		 	Date: 5/18/2015EMPLOYMENT
AGREEMENT BETWEEN

REGEN
BIOPHARMA, INC.

AND

Harry
M. Lander, Ph.D., M.B.A.

 

THIS EMPLOYMENT
AGREEMENT (the "Agreement") dated as of October 9, 2015 is entered into between Regen BioPharma,
Inc., a Nevada corporation, (the "Company") and Harry M. Lander ("Employee").

 

WITNESSETH:

WHEREAS, Employee
and the Company desire to enter into an agreement providing for the employment by the Company of Employee
upon the terms provided herein.

REPRESENTATIONS AND WARRANTIES

A)
Company hereby represents and warrants to Employee as follows;

(i)
Corporate Existence of Company. Company:

(a)
is a corporation duly formed, validly existing and in good standing under the laws of the State of Nevada and

(b)
has all requisite power and authority, and has all governmental licenses, authorizations, consents and approvals necessary to
execute and deliver this Agreement and to consummate the transactions contemplated by this Agreement.

 

(ii) No
Conflicts. None of the execution, delivery and performance of this Agreement by Company, or the consummation
or the transactions contemplated hereby and thereby

 

(a)
constitutes or will constitute a violation of the organizational documents of Company,

 

(b)
constitutes or will constitute a breach or violation of, or a default (or an event which, with notice
or lapse of time or both, would constitute such a default) under, any indenture, mortgage,
deed of Company, loan agreement, lease or other agreement or instrument to which Company is a
party or by which Company or any of its properties may be bound,

 

(c)
violates or will violate any statute, law or regulation or any order, judgment, decree or injunction of any court
or Governmental Authority directed to Company or any of its properties in a proceeding to which
its property is or was a party.

 

(B)
Employee hereby represents and warrant to Company as follows:

(i)
No Conflicts. None of the execution, delivery and performance of this Agreement by Employee, or the consummation of the transactions
contemplated hereby and thereby

(a)
constitutes or will constitute a breach or violation of, or a default (or an event which, with notice or lapse of time or both,
would constitute such a default) under, any indenture, mortgage, deed of Trust, loan agreement, lease or other agreement or instrument
to which Employee is a party or by which Employee or any of its properties may be bound,

    

    

    

(b)
violates or will violate any statute, law or regulation or any order, judgment, decree or injunction of any court or Governmental
Authority directed to Employee or any of their properties in a proceeding to which its property is or was a party.

AGREEMENT:

NOW,
THEREFORE, in consideration of the foregoing and the mutual promises and agreements set forth herein, the parties hereto, intending
to be legally bound, hereby agree as follows:

1.
Employment. During the Employment Period (as defined in Section 2), the Company hereby employs Employee and Employee hereby accepts
employment.

2.
Term. The Term of this Agreement shall commence on November 15, 2015 and shall expire on November 14, 2018 unless sooner terminated
in accordance with the provisions of Section 6 hereof; provided, however, that the term of this Agreement may be extended by mutual
agreement. The period from the commencement of the term of this Agreement to the date of its expiration or sooner termination
shall be considered to be the “Employment Period" hereunder.

3.
Duties. Employee shall be granted the title of President of the Company subject to the authority of the Company's Chief Executive
Officer (the “CEO”). Employee shall perform such duties commensurate with his office and as directed the CEO such
duties to include, but not be limited to: 

See
Schedule 1.

During
the Employment Period, Employee shall perform his duties hereunder in a diligent manner, subject to the provisions of Schedule
1 of this Agreement; devoting such amount of his business time, attention and efforts to the affairs of the Company within the
scope of his employment as is necessary for the proper rendition of such service and shall use his best efforts to promote the
best interests of the Company. Employee's services shall be rendered when and as required by the Board and in accordance with
his instructions, direction and control.

It
is agreed that Employee will only devote such time as to effectively conduct duties and responsibilities associated with this
position pursuant to this Agreement.

4.
Compensation Salary. During the Employment Period, Company shall pay Employee salary at the rate of (i) $16,667 per month
prorated for any partial employment month ("Salary"). Salary shall accrue during the period ending 90 days from the
execution of this Agreement and thereafter shall be paid on a monthly basis (“Payday”) starting 90 days from
execution of this agreement.  In the event that Payday falls on a Saturday, Sunday or holiday, on the next business day.
Salary may be paid, at the Company’s sole discretion, either in:

 

(a)
       cash, or

(b)
       shares of the Company’s common stock (“Stock Payment”)

 

Employee
acknowledges that any Stock Payments issued pursuant to this Agreement that are not registered pursuant to the Securities
Act of 1933 shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Securities
Act of 1933, and shall contain the following restrictive legend:

 

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN

    

    

    

 EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

 

The
Company may register any Stock Payment pursuant to the Securities Act of 1933, but is not obligated to do so pursuant to this
Agreement.

 

5.
Benefits.

a.
During the Employment Period, Employee shall be entitled to participation in any profit sharing plan, retirement plan, group life
insurance plan or other insurance plan, medical expense plan, medical and dental insurance and other benefit arrangements maintained
by the Company for its employees generally and, if applicable, their family members. In addition, Employee shall be entitled to
15 days paid vacation (“Vacation”) subject to having given fourteen days prior notice to the Company of Employee’s
intent to Vacation.

b.
Stock Compensation.  Employee shall receive 1,000,000 newly issued Series A Preferred shares of the Company upon execution
of this agreement (“Signing Shares”).  The shares shall be subject to a vesting schedule (See Schedule 2)

Employee
acknowledges that any Signing Shares  issued pursuant to this Agreement will not be  registered pursuant to the Securities
Act of 1933 , shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Securities
Act of 1933 and shall contain the following restrictive legend:

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

c.Incentive
Shares. Employee shall receive 10,000,000 newly issued Series A Preferred shares of the Company upon execution of this agreement
(“Incentive Shares”).  The shares shall be subject to a vesting schedule (See Schedule 2)

d.Milestone
Shares. Employee shall receive another 10,000,000 newly issued Series A Preferred shares of the Company upon achievement of milestones
(“Milestone Shares”).  The shares shall be subject to a vesting schedule (See Schedule 2)

6.
Termination.

a.
Employee's employment hereunder shall terminate upon the earlier of:

(i)
the expiration of the Employment Period,

    

    

    

(ii)
the death of Employee,

(iii)
the expiration of a continuous period of thirty (30) calendar days during which Employee is unable to perform his material duties
due to physical or mental incapacity,

(iv)
termination by the Company due to “just cause,”

(v)
termination by Employee due to a material breach of this Agreement by the Company . The exercise of the right of the Company or
Employee to terminate this Agreement pursuant to clauses (iv) or (v) hereof, as the case may be, shall not abrogate the rights
and remedies of the terminating party in respect of the breach giving rise to such termination.

b.
"Just cause" hereunder shall be defined and limited to mean:

(i)
Employee's failure or refusal, as determined by either the CEO in his sole discretion, to perform specific directives of the CEO
which are consistent with the scope and nature of Employee's duties and responsibilities as set forth herein (including the duties
described in Section 3), which failure or refusal continues after notice thereof and a reasonable time to cure; such reasonable
time to be determined by the CEO.

(ii)
Employee's conviction for a felony or any crime involving moral turpitude, fraud, or misrepresentation, or the presentation of
proof satisfactory to the CEO in the exercise of his reasonable judgment of Employee's misappropriation or embezzlement of funds
or assets from the Company;

(iii)
any intentional act having the purpose and effect of injuring the reputation, business or business relationships of the Company
in any material respect; and

(iv)
any breach by Employee of any material provision of this Agreement, including, without limitation, the restrictive covenants contained
in Section 7 hereof.

c.
In the event of any dispute regarding the existence of Employee's incapacity hereunder, the matter wil1 be resolved by the determination
of a physician qualified to practice medicine in California selected by the CEO. For this purpose, Employee will submit to appropriate
medical examinations.

d.
If Employee's employment hereunder is terminated pursuant to Section 6, the Company shall have no further obligations or liabilities
hereunder.

7. Restrictive
Covenant.

a.
Non-disclosure. Employee has, and during the Employment Period will have, access to confidential information and trade secrets
of the Company and its subsidiaries (the "Confidential Information") that may include, among other things:

(i)
Financial information

(ii)
Supply and services information

(iii)
Marketing information

(iv)
Personnel information

(v)
Customer information

    

    

    

(vi)
Product information

(vii)
The Company’s procedures, systems, policies and processes of operation.

Employee
shall at all times during his employment by the Company and thereafter hold in strictest confidence any and all Confidential Information
that may have come or may come into Employee's possession or within Employee's knowledge. Employee agrees that neither he nor
any person or entity, directly or indirectly, controlled by or under common control with the Employee (an "Affiliate")will
for any reason, except in the course of performing his duties hereunder, for himself or any other person, use or disclose to anyone,
exclusive of Company employees, agents, representatives, or independent consultants to the Company or any of its subsidiaries
or Affiliates of the Company, any Confidential Information; provided, however, that Employee may disclose Confidential Information
which (i) has become generally available to the public other than as a result of a breach of this Agreement by Employee or (ii)
Employee is compelled to disclose pursuant to subpoena or an order by a court competent jurisdiction; provided that, if Employee
is so required to disclose any Confidential Information pursuant to the foregoing clause (ii), Employee shall provide advance
written notice to the Company, to the extent possible, to allow the Company to seek an appropriate protective order therefore
(iii) Potential advisors, employees, or investors of the Company where there is a reasonable expectation of confidentiality. All
Confidential Information shall remain the Company's property and shall be returned (or, at the Company's option, destroyed) upon
the Company's written request.

b.
Non-Solicitation of Employees. Employee agrees that from the date hereof and continuing for a period of three years following
the termination of this Agreement for whatever reason (the "Non-Compete Period"), neither Employee nor any Affiliate
of Employee will solicit or hire for employment any officer, director or employee of the Company who was employed by the Company
at any time within twelve months prior to the act of solicitation.

c.
Non-Competition. Employee agrees that, other than with the approval of the CEO, which approval shall not be unreasonably withheld,
during the Employment Period, neither Employee nor any Affiliate of Employee will, directly or indirectly, become a shareholder,
director, officer, agent, partner or employee of, or otherwise hold any ownership interest in, any person, firm or entity engaged
in any Competitive Business (as defined below), engage as a sole proprietor in any Competitive Business, act as a consultant to
or assist any of the foregoing or otherwise engage or participate in any Competitive Business; provided, however, that the foregoing
shall not prohibit the ownership by Employee of less than ten percent (10%) of the outstanding shares of the stock of any corporation
engaged in any Competitive Business, which shares are regularly traded on a national securities exchange or in any over-the-counter
market. For the purpose hereof, "Competitive Business" means the ownership, operation, development, marketing of the
services related to, or management of cellular therapeutics within the United States.

d.
Consideration, Relief, Reformation; Severability. The Company has specifically bargained for the covenants set forth in this Section
6 in consideration for the compensation, experience, and information that Employee will gain or receive in connection with his
employment by the Company. Employee agrees that the covenants set forth herein will not preclude Employee from engaging in any
lawful profession, trade or business or from being gainfully employed necessary to provide Employee, his family members and dependents
a standard of living to which he and they have been accustomed and may expect. Employee acknowledges and agrees that the restrictive
covenants in this Section 6 have been specifically negotiated, are reasonable in all respects, including, without limitation,
their geographic scope and duration, and may be enforced by specific performance or otherwise. Employee shall not raise any issue
of reasonableness as

    

    

    

 a defense in any proceeding to enforce any of such covenants. Notwithstanding the foregoing, in the event
that a covenant included in this Agreement shall be deemed by any court to be unreasonably broad in any respect, it shall be modified
or limited in its geographic scope, duration or otherwise to the extent necessary to make it reasonable while preserving its restrictive
nature to the maximum degree possible and shall be enforced accordingly; provided however, that if, notwithstanding the foregoing,
a court of competent jurisdiction shall hold any of the covenants contained in Sections 7 (a), (b) or (c) to be unenforceable
(as so modified), then the unenforceable covenant shall be deemed eliminated from the provisions of this Agreement for the purpose
of those proceedings to the extent necessary to permit the remaining covenants to be enforced so that the validity, legality or
enforceability of the remaining provisions of this Agreement shall not be affected thereby.

8.
Developments.

Employee
hereby assigns to the Company his entire right, title and interest in all know how, discoveries and improvements,
customer lists, trade secrets and ideas, writings and copyrightable material, which may be conceived by Employee
or developed or acquired by him during the term of this Agreement, which may pertain directly to the Company's business
and were developed with Company resources. Employee agrees to promptly and fully disclose in writing all such developments. Employee
will, upon the Company's request, execute, acknowledge and deliver to the Company all instruments
and do all other acts which are necessary or desirable to entitle the Company to all rights in the foregoing
and enable the Company to file and prosecute applications for, and to acquire, maintain and enforce all letters, trademark
registrations or copyrights with respect to the foregoing in all countries.

9.
Remedies.

Employee
acknowledges that any material breach of this Agreement will cause irreparable harm to the Company, that such harm will be difficult
if not impossible to ascertain, and that the Company shall be entitled to equitable relief, including injunction, against
any actual or threatened breach hereof, without bond and without liability should such relief be denied, modified or vacated.
Neither the right to obtain such relief nor the obtaining of such relief shall be exclusive of or preclude the
Company from any other remedy.

10.
Legal Counsel.

Employee
acknowledges that Employee has carefully read this Agreement and understands all of the terms hereof and that Employee
has been given the opportunity to discuss this Agreement with Employee's private legal counsel and
has availed himself of that opportunity to the extent Employee wishes to do so.

11. Notices.

All
notices, requests and other communications under this Agreement shall be in writing and shall be deemed to have been received
five business days after having been deposited in the United States Mail and enclosed in a registered or certified post-paid
envelope; one day after having been sent by overnight courier on a business day or otherwise at the open of
business on the next succeeding business day; when personally delivered or sent by facsimile communications equipment
of the sending party on a business day or otherwise at the open of business on the next succeeding business day; and, in
each case, addressed to the respective parties at the addresses stated below or to such other changed addresses
that the parties may have fixed by notice in accordance herewith.

    

    

    

If
to the Company:

Regen
BioPharma, Inc.

4700
Sprint Street, Suite 304

La
Mesa, CA 91942

 

Attn:
David Koos, CEO

 

 

 

If to Employee:

Harry
M. Lander, Ph.D., M.B.A.

Doha,
Qatar

+1(917)
696-1991

hazhml@aol.com

 

12.
Waiver of Breach.

A
waiver by the Company or Employee of a breach of any provision of this Agreement by the other party shall
not operate or be construed as a waiver of any subsequent breach by the other party.

13. Entire Agreement.

This
instrument contains the entire agreement of the parties with respect to the subject matter hereof and supersedes any
prior agreements of the parties with respect to the subject matter hereof. It may be changed only
by an agreement in writing signed by a party against whom enforcement of any waiver, change,
modification, extension or discharge is sought.

 14.
Applicable Law.

The
terms and conditions of this Agreement shall be governed by and construed in accordance with the laws of the State or
California. Any action to enforce this Agreement shall be brought in the state courts located in San Diego County, State
of California.

IN
WHITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

By:/David
R. Koos/

________________________ 

David
R. Koos

Chief
Executive Officer

 

By: /Harry
M. Lander/

_________________________

Harry M.
Lander, Ph.D., M.B.A.

    

    

    

Schedule
1.

 

Employer:
Regen BioPharma, Inc.

 

Location:
Company Headquarters and any remote offices

 

Description:

 

Job
Description – President

 

Job Summary

 

The
President, reporting directly to the CEO, will develop a robust strategic plan and vision for the advancement of Regen’s
research into commercial products. The President leads the growth of Regen’s technology, whether from in-house research
or through corporate or academic partnerships, business development, and commercialization initiatives to support Regen’s
vision.

He/she
leads the development of the commercial innovation capability at Regen to execute a quantifiable business development strategy
to catalyze the development of new products and services. Regen expects to become a regional leader in moving innovation and research
into the commercial marketplace and will look to the incumbent to play a leading role in realizing that goal. The President ensures
that the research programs of Regen align with that of its vision and plays an important role in external relations.

Key Accountabilities

		·	The
                                         President, in concert with the CEO, will develop a robust strategic plan and vision for
                                         the advancement of Regen’s research into commercial markets. The President leads
                                         the growth of Regen’s technology, business development, and commercialization initiatives
                                         to support Regen’s vision. 

 

		·	The
                                         President will devise an implementation plan that articulates how Regen will achieve
                                         its strategic plan. This will likely include milestones, a catalyst calendar and a plan
                                         for each product line.

		·	In
                                         conjunction with the CFO, the President will identify strategies to raise capital to
                                         fund the enterprise. A use of funds document will be created and converted to a 1 and
                                         2 year budget.

 

    

    

    

		·	The
                                         President will be responsible for adjusting and maintaining the Regen Scientific Advisory
                                         Board. In addition to reviewing and revising membership, he/she will organize quarterly
                                         meetings of the SAB and ensure that the materials presented to the SAB are timely and
                                         that any actionable items resulting from the meetings are followed up on.

 

		·	He/she
                                         leads the development of the commercial innovation capability at Regen to execute a quantifiable
                                         business development strategy to catalyze the development of new products and services.
                                         Regen expects to become a regional leader in moving innovation and research to the commercial
                                         marketplace and will look to the incumbent to play a leading role in realizing that goal.
                                         

 

		·	The
                                         incumbent provides expert intelligence on the biotechnology, pharmaceutical, medical
                                         device, software and intellectual property market dynamics, stays abreast of industry-wide
                                         changes and trends, proactively identifies opportunities for Regen. He/she assesses the
                                         technology transfer and business development needs within Regen’s scientific &
                                         clinical communities, and develops strategies for addressing deficits and advancing commercialization
                                         potential.

 

		·	The
                                         President is responsible for developing and managing external business relationships
                                         with key industry partners (including pharmaceutical, biotechnology, CROs, medical device,
                                         and diagnostic companies), leading commercialization partnerships and new ventures with
                                         industry, including building sponsored research collaborations with industry and academia.
                                         He/she represents Regen at national meetings as needed to further business development
                                         goals. 

 

		·	The
                                         President leads the negotiation and structuring of complex license, collaborative research,
                                         and similar agreements to reflect complex business issues, assessing the protectability
                                         and commercial potential of new invention disclosures, obtaining and maintaining intellectual
                                         property protection through legal counsel, pursuing expanded relationships with the corporate
                                         sector, attracting venture capital (or other funding) for investment and facilitating
                                         relationships among scientists, industry, research sponsors, patent counsel and university
                                         and industry administrators.

 

    

    

    

Schedule
2.

Vesting
Schedule for signing shares

		1.	Signing
                                         Shares may not be sold, transferred, assigned, pledged or otherwise encumbered or disposed
                                         of by Employee (“Transfer Restriction”) until after a one year vesting period
                                         has expired.

 

		2.	Incentive
                                         Shares vesting in two (2) years from hire.

		3.	Milestone
                                         Shares will be issued upon occurrence of any of the following events having occurred
                                         during the employment by the Company of the Employee. Milestone shares will vest immediately
                                         and are not subject to Transfer Restrictions.

a)
two collaborations with  pharmaceutical firms with annual revenues of $250,000,000 or greater over their last three fiscal
years

b)
an equity raise of $10,000,000 invested in the securities of the Company by sources  introduced
to the Company by the Employee and who have not previously been introduced to the Company by any other entity.

c)
Listing of the Company’s equity securities on any of the following markets:

	i.	 	Nasdaq Global Select Market
	ii.	 	Nasdaq Global Market
	iii.	 	Nasdaq Capital Market
	iv.	 	The New York Stock Exchange
	v.	 	NYSE MKT

d)
sale of a portion of the Regen Intellectual Property portfolio for appropriate consideration

e)
clearance of any Regen sponsored intellectual property through FDA phase II clinical trials.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}]]